Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy
Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy
Understanding Pharmacogenomics | Cancer.Net
Frontiers | Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics | Oncology
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 | The BMJ
Clinical Cancer Drugs
Past, Present, and Future of Anticancer Nanomedicine | IJN
Home Page: Clinical Oncology
Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study | The BMJ
Americans Can't Keep Up with High Cost of Cancer Treatment
Oncology and Cancer Therapeutics Journals | Oncology Research Journals
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis - eClinicalMedicine
Clinical and Translational Medicine - Wiley Online Library
Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and Targeted Therapy
Frontiers | Probiotics in Cancer | Oncology
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
The State of Cancer Care in America, 2017: A Report by the American Society of Clinical Oncology | JCO Oncology Practice
Frontiers | The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer | Oncology
.jpg "Anti-Cancer Drugs")
Anti-Cancer Drugs
Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
Home Page ::: Current Cancer Drug Targets
Frontiers | PLGA-Based Nanoparticles in Cancer Treatment | Pharmacology
Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018 | PLOS ONE
